Hikma has struck a deal with Glenmark to gain US rights to the Indian firm’s investigational Ryaltris (olopatadine/mometasone) nasal spray. The agreement builds on what Hikma said was its “market-leading position in nasal allergy sprays.”
Hikma Strikes Deal For Ryaltris In US
Agreement With Glenmark Builds On Nasal Spray Portfolio
Hikma has struck a deal with Glenmark to gain US rights to its Ryaltris nasal spray. The agreement comes as Hikma reported sales ahead by 7% in 2019 on strong performances from the firm’s Injectables and Branded segments.
